Eli Lilly Partners with Insilico for $2.75 Billion AI Drug Deal
- Significant Partnership Value: Eli Lilly has entered a $2.75 billion agreement with Hong Kong's Insilico Medicine, providing $115 million upfront, with the remainder contingent on regulatory and commercial milestones, reflecting strong confidence in AI-driven drug development.
- AI Drug Development Progress: Insilico has developed at least 28 drugs using generative AI tools, with nearly half already in clinical stages, showcasing its innovative capabilities and market potential in drug research.
- Complementary Technical Advantages: Insilico will join Lilly's Gateway Labs community, and their collaboration is expected to accelerate the identification of therapeutic candidates across multiple disease areas, enhancing clinical development efficiency and solidifying Lilly's leadership in biotechnology.
- Strategic Focus on China: Lilly plans to invest $3 billion in China over the next decade, despite generating less than 3% of its revenue from the region last year, indicating a strong commitment to the Chinese market and optimism about long-term growth potential.
Trade with 70% Backtested Accuracy
Analyst Views on LLY
About LLY
About the author


- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.

New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.

Safety Profile Consistency: The safety profile of the product remains consistent, indicating reliability in its performance.
Lack of New Safety Signals: There have been no new safety signals reported in the first year of monitoring, suggesting ongoing safety assurance.

- Durable Disease Control: Eli Lilly has achieved four years of effective control over a specific disease, demonstrating the durability of their treatment approach.
- Focus on Dermatology: The advancements are particularly relevant in the field of dermatology, highlighting the company's commitment to addressing skin-related health issues.

Treatment Duration: Patients with moderate-to-severe atopic dermatitis can receive up to four years of effective disease control.
Disease Management: The treatment aims to provide durable control of the condition, improving the quality of life for affected individuals.
- Efficacy Durability: In the ADlong Phase 3b study, nearly all patients treated with EBGLYSS achieved significant skin improvement (EASI-75) over four years, with 75% reaching near-complete skin clearance (EASI-90), indicating a transformative impact on the quality of life for eczema patients.
- Itch Relief: 78% of patients experienced significant itch relief (Pruritus NRS≤4) during treatment, which is crucial for enhancing daily living and mental health, demonstrating EBGLYSS's effectiveness in alleviating eczema symptoms.
- Steroid-Free Treatment: 80% of patients achieved results without the need for topical corticosteroids while on EBGLYSS, indicating the drug's ability to provide durable outcomes and reduce reliance on traditional therapies, thereby reshaping the treatment paradigm for eczema.
- Safety Profile: The safety of EBGLYSS in the first year of the ADlong study was consistent with known safety profiles, with no new safety signals observed, and the majority of adverse events were mild or moderate, reinforcing its potential as a first-line biologic treatment.






